Ignite Creation Date:
2024-05-05 @ 11:08 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00004359
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-10-18
Brief Title:
Phase II Pilot Study of Extracorporeal Phototherapy for Epidermolysis Bullosa Acquisita
Sponsor:
National Center for Research Resources NCRR
Organization:
Office of Rare Diseases ORD
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2000-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
OBJECTIVES I Evaluate immunomodulation with extracorporeal photochemotherapy ECP in patients with epidermolysis bullosa acquisita
II Investigate the effect of ECP on lymphocyte activity
II Investigate the effect of ECP on lymphocyte activity
Detailed Description:
PROTOCOL OUTLINE Oral methoxsalen 8-MOP is administered 90 minutes prior to leukapheresis Blood mononuclear cells are exposed to ultraviolet A light for 3 hours then returned to the patient The process is repeated on 2 successive days
Patients are re-treated every 3 to 4 weeks for a total of 6 treatments or until the skin has cleared
Patients are re-treated every 3 to 4 weeks for a total of 6 treatments or until the skin has cleared
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NU-511 | None | None | None |